PTC Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 61 to 75.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating of over 80 in the early stages of their moves. See if PTC Therapeutics can continue to show renewed price strength and hit that benchmark.
PTC Therapeutics is working on a consolidation with a 52.98 buy point. See if the stock can break out in heavy volume.
PTC Therapeutics showed 0% EPS growth in its most recent report, while sales growth came in at -4%.
PTC Therapeutics earns the No. 146 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
